Anti-S100A8 Antibody Targets Leukemia Resistance Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute leukemia, particularly acute myeloid leukemia (AML), have seen limited improvement over the past few decades, with poor prognosis and low survival rates, necessitating novel approaches to enhance leukemia-free survival.
Innovation Solution
Development of an anti-S100A8 antibody that specifically binds to the S100A8 protein or its dimers, formulated for administration alone or with chemotherapeutic agents like daunorubicin, doxorubicin, and cytarabine, to stimulate cell differentiation and inhibit proliferation in leukemia cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy drugs are used for treating acute leukemia, then treatment protocols can be maintained, but survival rates remain poor and prognosis is limited
Solution Approach 1:
The patent introduces S100A8/S100A9 heterodimer as an intermediary target that mediates the interaction between chemotherapy drugs and leukemia cells. The antibody against this heterodimer acts as a mediator that enhances the effectiveness of conventional chemotherapy by blocking the S100A8/S100A9 pathway that leukemia cells use to resist treatment, thereby improving survival rates without requiring entirely new treatment protocols
Solution Approach 2:
The invention combines conventional chemotherapy agents with an antibody targeting the S100A8/S100A9 heterodimer, creating a composite treatment approach. This composite therapy leverages the cell-killing effects of traditional chemotherapies while simultaneously blocking the leukemia cells' resistance mechanisms, resulting in enhanced treatment effectiveness and improved prognosis
2Reliability
If treatment intensity is increased to improve leukemia-free survival, then survival outcomes may improve, but patient toxicity and treatment complexity increase
Solution Approach 1:
The antibody against S100A8/S100A9 heterodimer serves as a mediator that enhances treatment effectiveness at lower intensities. By blocking this specific pathway, the treatment achieves better leukemia-free survival without requiring extreme doses of chemotherapy that would increase complexity and toxicity, thus resolving the contradiction between survival improvement and treatment simplicity
3Adaptability or versatility
If novel treatment approaches are developed to improve prognosis, then treatment effectiveness increases, but treatment cost and development complexity increase
Solution Approach 1:
The patent identifies S100A8/S100A9 heterodimer as a specific intermediary target in leukemia pathogenesis. By developing an antibody against this well-defined target, the invention creates a focused therapeutic approach that is more tractable than broad-spectrum novel therapies. The clear mechanistic target reduces development complexity compared to other novel approaches while maintaining improved treatment effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-S100A8 antibody effectively delays leukemia progression, improves survival rates, and promotes differentiation of leukemia cells, reducing their proliferation and enhancing the effectiveness of chemotherapy in treating acute lymphoblastic, myeloid, chronic lymphocytic, and chronic myeloid leukemias.
Implementation Method 1
The anti-S100A8 specifically binds to a portion of S100A8 protein
Data Source
Figure 1~3
Figure 4~6
Figure 7~8
AI summary
The present description relates to an anti-S1008 protein for treating leukemia. More specifically, is disclosed anti-S100A8 antibody that specifically binds to a portion of S100A8 protein and/or a S100A8/S100A9 heterodimer for treating leukemia.